Chongqing Zhifei Biological Products Co. Ltd.
http://www.zhifeishengwu.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Chongqing Zhifei Biological Products Co. Ltd.
China HPV Demand Shaping Merck But Competitors Catching Up
Multiple factors were behind Merck & Co’s rise to ace AstraZeneca and others to become the leading pharma multinational in the world’s second-largest pharma market in 2023, including partnerships and competition and a strong position in the growing HPV vaccine sector.
VBP Pains Swell Prompting New China Strategy, Local Innovation Focus
As the rollout of volume-based procurement to more products brings more pain, drug makers are exploring different China strategies. One indicator, though, is clear - local innovation and distribution can’t be ignored anymore.
Watch Out GSK! China’s Homegrown Shingles Vaccine Set To Soar
Although the domestic developer did not provide sales figures for 2023, a new homegrown shingles vaccine in China is poised to eat into the market share of GSK’s Shingrix in the country.
Pfizer Divests Select China Prevenar 13 Rights, Staff As Domestic Firms Gain Traction
Following in the steps of Merck & Co. and GSK, Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in the country - but the US firm is going one step further.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Beijing Luzhu Biopharmaceutical Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice